Sinovac Biotech Ltd. (SVA) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Sinovac Biotech Ltd. (SVA:NASDAQ), powered by AI.

Current Price
$6.47
P/E Ratio
-6.4
Market Cap
644M
Sector
Unknown
What is the Sinovac Biotech Ltd. stock price forecast?

Sinovac Biotech Ltd. is currently trading at $6.47. View real-time AI analysis on Alpha Lenz.

What is Sinovac Biotech Ltd. insider trading activity?

View the latest insider trading data for Sinovac Biotech Ltd. on Alpha Lenz.

What is Sinovac Biotech Ltd.'s P/E ratio?

Sinovac Biotech Ltd.'s P/E ratio is -6.4.

Sinovac Biotech Ltd.

NASDAQ · SVA
$6.47+0.00(+0.00%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Sinovac Biotech Ltd.'s future dividend policy...
Alpha Chat Insight

Sinovac Biotech Ltd. trades at a P/E of -6.4 (undervalued) with modest ROE of -1.1%.

Ask for details

Company Overview

Sinovac Biotech Ltd. is a prominent biotechnology company that specializes in the research, development, manufacturing, and commercialization of vaccines to address human infectious diseases. Headquartered in Beijing, China, Sinovac plays a critical role in the global health market by developing vaccines for illnesses such as hepatitis, influenza, mumps, and rabies. The company's significant contribution to public health was particularly highlighted during the COVID-19 pandemic with its development and distribution of the CoronaVac vaccine. Sinovac's vaccine production focuses on traditional techniques, leveraging established inactivated virus methodologies, which makes its solutions accessible to a wide demographic range and suitable for varied health systems. This emphasis on traditional science permits the company to rapidly respond to emerging immunological challenges. Through strategic collaborations and regulatory approvals across multiple jurisdictions, Sinovac has expanded its presence in international markets, reinforcing its status as a vital player in global healthcare and vaccine distribution. Its initiatives not only address current health concerns but also contribute to future preventive healthcare frameworks.

SectorUnknown
IndustryUnknown
0

Company Statistics

FY 2023

Profile

$644.46MMarket Cap
$448.27MRevenue
0.00Shares Out
0Employees

Margins

59.51%Gross
16.22%EBITDA
-116.96%Operating
-34.14%Pre-Tax
-57.63%Net

Valuation

-6.45P/E
0.07P/B
1.44EV/Sales
41.09EV/EBITDA
-15.46P/FCF

Growth (CAGR)

-4.25%Rev 3Yr
14.31%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-1.86%ROA
-1.13%ROE
-1.09%ROIC

Financial Health

$1.27BCash & Cash Equivalents
$365.08MNet Debt
13.60%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Sinovac Biotech Ltd. (ticker: SVA) is a company listed on NASDAQ in the Unknown sector (Unknown). Market cap is $644M.

The current price is $6.47 with a P/E ratio of -6.45x and P/B of 0.07x.

ROE is -1.13% and operating margin is -116.96%. Annual revenue is $448M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Sinovac Biotech Ltd. (SVA) Stock Forecast 2026 $6.47 — Price, Financials & Analyst Targets | Alpha Lenz